We want to share a quick update and applaud one of our 50-State Network advocates Danielle Yevsa who spoke up about Fail First/ Step Therapy practices in the New York Daily News.
Salem resident Joni Johnston testified to the Missouri General Assembly’s House Emerging Issues Committee Jan. 20.
When Lauren Marchi entered college as a freshman at American University in Washington, DC, she was a classically trained pianist and ballerina. She had aspirations of pursuing degrees in piano performance and marketing while dancing on the side, but early in her senior year she was forced to question her well-laid plans.
Katherine “Kat” Macfarlane, JD, who has rheumatoid arthritis and inflammatory eye disease, spoke at a briefing held at the House of Representatives on Monday about regulation of biosimilars.
Rheumatoid arthritis patient advocates for continued access to medication in North Dakota
The U.S. Food and Drug Administration is months away from approving the first biosimilar drugs, but a bill advanced by a legislative committee Monday would help Utah prepare for that day.
For patients who are uninsured or underinsured, new treatments on the cutting edge of medicine called biosimilars have the potential to expand access and save lives.
On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs.
The U.S. Food & Drug Administration approved the first generic version of a biotech drug for domestic sale Friday, hours after Colorado state legislators wrestled with how to let pharmacists handle cheaper biotech drug knockoffs.
Louisiana advocate Kat MacFarlane speak about the importance of physician/patient relationships, the promise of biosimilars when made available transparently, and why she is testifying about biosimilar substitution in the legislature.
Oregon Advocate Anna Meyer speaks on an interview for KODL for Biosimilars
Would you want your pharmacist to tell you and your doctor if they substituted your biologic medication with a similar, but not identical drug? Of course you would. But as biosimilars — a less expensive mimic of Biologics — are introduced on the U.S. market, individual states are deciding how and when they can be […]
Watch the Video
Without the medicine Rachelle Crow takes for her rheumatoid arthritis, the 29-year-old Michigan woman’s face would frequently feel as if it were engulfed in flames. She would barely be able to crawl out of bed. She would have trouble opening or closing her fists or lifting her 3-year-old daughter. Crow can do all those things […]
Julie Wiles of Spring says she found relief from rheumatoid arthritis when she began receiving injections of Enbrel, a drug that costs $2,500 a week. But even with insurance coverage, Wiles can no longer afford Enbrel. Instead, she takes a combination of less expensive drugs and injections that hasn’t been nearly as effective. Read […]
Mariah Leach felt at the top of her game six years ago. At age 25, she was pursuing a law degree and a master’s in environmental policy at the University of Colorado, earning straight A’s and playing water polo with the university’s club team. But then her toes began to hurt. A few weeks, later […]
Last year, when Mariah Leach was pregnant with her son, her rheumatoid arthritis flared up again. She had stopped medication during pregnancy, but when the autoimmune disease, which causes painful and damaging inflammation in joints and elsewhere, resurged, she and her doctors made the difficult decision for her to restart during her third trimester, based […]
Mariah Leach, 32, a Colorado woman who uses biologics to treat rheumatoid arthritis, said she hopes pharmacies and insurers don’t force her to take a biosimilar version. “The opportunity to have a less expensive treatment option is fabulous,” she said. “I just don’t want to be put on it without my choice. I don’t want […]
In a move expected to increase competition and lower drug prices, the Food and Drug Administration today approved the first “biosimilar” drug, designed to closely mimic existing drugs grown in living cells. Pharmaceutical companies have been able to produce low-cost generic drugs for three decades, but they haven’t before been able to produce knockoff versions […]
Much cheaper, life-saving drugs could become available this year. They are called biosimilars and are copycat versions of drugs for diseases like rheumatoid arthritis, breast cancer and psoriasis….
There’s an issue quietly taking place in state legislatures all across the country. You may not have heard much about it – but if you are a patient living with rheumatoid arthritis it is an issue that will be very likely to affect you in the not too distant future.